$QTRX earnings report

Quanterix reports Q3 2026 revenue of $35.0 million, up 6.3% sequentially, with GAAP net loss of $21.6 million and narrowed FY2026 revenue outlook of $142-146 million. AlphAI read Quanterix's Q3 FY2026 filing as mixed.

Q3 FY2026

AlphAI · Earnings readQTRX · Q3 2026 · ended 2026-09-30

Quanterix reports Q3 2026 revenue of $35.0 million, up 6.3% sequentially, with GAAP net loss of $21.6 million and narrowed FY2026 revenue outlook of $142-146 million

→Mixed quarter

Total revenue rose 6.3% sequentially and adjusted gross margin improved to 47.4%, but revenue for the quarter ($34,974 thousand) was below the prior-year quarter ($40,233 thousand), GAAP gross margin fell, service and other revenue declined sharply year over year, and cash ended the quarter at $80.7 million against a year-end expectation of approximately $70 million.

Revenue
$35.0M
6.3% q/q
Product revenue
$25,193 thousand (Q3 2026)
Gross margin · GAAP
38.6%
down 90 basis points y/y
FY2026 outlook
$142-146 million
GM 48-50% adjusted gross margin (non-GAAP)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenues (Q3 2026)GAAP$34.97M6.3%–
Product revenue (Q3 2026)GAAP$25.19M––
Service and other revenue (Q3 2026)GAAP$9.36M––
Collaboration and license revenue (Q3 2026)GAAP$422K––
Cost of product revenue (Q3 2026)GAAP$15.45M––
Cost of service and other revenue (Q3 2026)GAAP$6.03M––
Total costs of goods sold and services (Q3 2026)GAAP$21.47M––
Gross profit (Q3 2026)GAAP$13.5M––
Gross margin (Q3 2026)GAAP38.6%–down 90 basis points
Adjusted gross profit (Q3 2026)non-GAAP$16.56M––
Adjusted gross margin (Q3 2026)non-GAAP47.4%–up 150 bps
Research and development (Q3 2026)GAAP$7.37M––
Selling, general and administrative (Q3 2026)GAAP$28.45M––
Impairment and restructuring costs (Q3 2026)GAAP$171K––
Total operating expenses (Q3 2026)GAAP$36.00M––
Adjusted total operating expenses (Q3 2026)non-GAAP$35.42M––
Loss from operations (Q3 2026)GAAP−$22.50M––
Adjusted loss from operations (Q3 2026)non-GAAP−$18.86M––
Interest income (Q3 2026)GAAP$663K––
Income tax benefit (expense) (Q3 2026)GAAP−$288K––
Net loss (Q3 2026)GAAP−$21.59M–35.6% improvement
Net loss per common share, basic and diluted (Q3 2026)GAAP$(0.46)––
Adjusted EBITDA (Q3 2026)non-GAAP−$12.17M–decline of 2.4%
Adjusted EBITDA margin (Q3 2026)non-GAAP(34.8)%––
Cash, cash equivalents, marketable securities and restricted cash (September 30, 2026)other$80.7M––
Total revenues (nine months ended September 30, 2026)GAAP$104.3M––
Product revenue (nine months ended September 30, 2026)GAAP$74.15M––
Service and other revenue (nine months ended September 30, 2026)GAAP$28.75M––
Collaboration and license revenue (nine months ended September 30, 2026)GAAP$1.39M––
Gross profit (nine months ended September 30, 2026)GAAP$41.74M––
Gross margin (nine months ended September 30, 2026)GAAP40.0%––
Adjusted gross profit (nine months ended September 30, 2026)non-GAAP$50.94M––
Adjusted gross margin (nine months ended September 30, 2026)non-GAAP48.8%––
Research and development (nine months ended September 30, 2026)GAAP$22.52M––
Selling, general and administrative (nine months ended September 30, 2026)GAAP$85.58M––
Impairment and restructuring costs (nine months ended September 30, 2026)GAAP$46.94M––
Total operating expenses (nine months ended September 30, 2026)GAAP$155.0M––
Adjusted total operating expenses (nine months ended September 30, 2026)non-GAAP$101.9M––
Loss from operations (nine months ended September 30, 2026)GAAP−$113.3M––
Adjusted loss from operations (nine months ended September 30, 2026)non-GAAP−$50.92M––
Interest income (nine months ended September 30, 2026)GAAP$2.32M––
Income tax benefit (expense) (nine months ended September 30, 2026)GAAP−$227K––
Net loss (nine months ended September 30, 2026)GAAP−$88.07M––
Net loss per common share, basic and diluted (nine months ended September 30, 2026)GAAP$(1.87)––
Adjusted EBITDA (nine months ended September 30, 2026)non-GAAP−$31.98M––
Adjusted EBITDA margin (nine months ended September 30, 2026)non-GAAP(30.7)%––
Net cash used in operating activities (nine months ended September 30, 2026)GAAP−$39.43M––

Segments

SegmentRevenueq/qy/y
Product revenueThe filing gives no driver for this revenue line.$25,193 thousand (Q3 2026)––
Service and other revenueThe filing gives no driver for this revenue line.$9,359 thousand (Q3 2026)––
Collaboration and license revenueThe filing gives no driver for this revenue line.$422 thousand (Q3 2026)––

FY2026 outlook

  • Revenue$142-146 million
  • Gross margin48-50% adjusted gross margin (non-GAAP)
  • NoteCompany is narrowing its expectation for total revenues to $142-146 million
  • NoteCompany continues to expect adjusted gross margins (non-GAAP) in a range of 48-50%
  • NoteCompany now expects to end 2026 with a cash balance of approximately $70 million
  • NoteCompany expects no debt at end of 2026

Capital returns

  • No share repurchases or dividends are reported in the filing.
  • Proceeds from common stock issued under stock plans were $525 thousand in the nine months ended September 30, 2026, against $930 thousand in the prior-year period.
  • Payments for employee taxes withheld on stock-based compensation awards were $(71) thousand in the nine months ended September 30, 2026, against $(1,010) thousand in the prior-year period.

What drove it

  • Company states that revenue was higher than expected in the third quarter and rose 6.3% sequentially despite continued market softness.
  • Company states that the quarter reflects sequential improvement across all of its businesses.
  • Company attributes expected commercial improvement to actions initiated last quarter, including reorganizing teams and adding experienced leadership.
  • Company reports that Jim Gute was named Chief Commercial Officer in mid-August and Dr. Yuri Fesko was named Chief Medical Officer in September.
  • Company reports expanded coverage: beginning November 1, 2026, traditional Medicaid members and state employees in Florida can receive coverage for qualifying blood-based biomarker tests, including LucentAD Complete, when medical necessity criteria are met.
  • Company reports two new commercial partnerships with regional clinical reference labs, Sherman Abrams Lab in New York and TruPath in Mississippi.
  • Company reports new regulatory approvals in China for neurology biomarker testing based on HD-X and SR-X instruments and testing kits for four biomarkers, with Innovita Biological Technology Co. broadening access.
  • Company reports that the nine-month other income line includes $21,596 thousand of income from contract termination, which the reconciliation describes as one-time income related to terminating a diagnostics development agreement assumed in the Akoya acquisition.

Concerns

  • Total revenues of $34,974 thousand in Q3 2026 were below $40,233 thousand in Q3 2025, and the filing does not print a year-over-year percentage for revenue.
  • Service and other revenue fell to $9,359 thousand from $14,036 thousand in the prior-year quarter.
  • Product revenue fell to $25,193 thousand from $26,151 thousand in the prior-year quarter.
  • GAAP gross margin was 38.6%, down 90 basis points from the prior year, while the adjusted gross margin of 47.4% is a non-GAAP measure.
  • Net loss of $(21,591) thousand was still reported in Q3 2026, and adjusted EBITDA was a loss of $(12,173) thousand.
  • Impairment and restructuring costs were $46,940 thousand in the nine months ended September 30, 2026, against $14,844 thousand in the prior-year period, and the filing reports impairment charges for goodwill and an intangible asset.
  • Cash and marketable securities declined: marketable securities fell to $41,495 thousand from $88,393 thousand at December 31, 2025, and the company now expects approximately $70 million of cash at year end.
  • Total assets fell to $300,437 thousand from $418,766 thousand at December 31, 2025, with goodwill now nil.
  • The company reports the outlook as narrowed, and the prior range is not printed in this filing, so the direction of the change cannot be determined from the document.

What to watch

  • Whether the sequential revenue improvement continues in Q4 2026 and whether the company reaches the $142-146 million FY2026 revenue range.
  • Trajectory of service and other revenue, which declined year over year in Q3 2026 and in the nine-month period.
  • Whether adjusted gross margin remains within the 48-50% range for FY2026, given that the nine-month adjusted gross margin was 48.8%.
  • Progress of diagnostics commercialization, including the Florida Medicaid coverage, the new reference lab partnerships and the China approvals.
  • Year-end cash of approximately $70 million against the $80.7 million reported at September 30, 2026.
  • Milestones for the single-site Alzheimer's disease five biomarker blood test, which the company describes as a focus for achieving key milestones.
  • Timing of shipments for the TIME panel and high-plex ADC panel, which the filing says are shipping in early 2027.

Balance sheet and cash flow

  • Cash and cash equivalents: $35,864 thousand at September 30, 2026, against $29,839 thousand at December 31, 2025.
  • Marketable securities: $41,495 thousand at September 30, 2026, against $88,393 thousand at December 31, 2025.
  • Restricted cash: $3,352 thousand at September 30, 2026, against $3,341 thousand at December 31, 2025.
  • Total assets: $300,437 thousand at September 30, 2026, against $418,766 thousand at December 31, 2025.
  • Intangible assets, net: $102,408 thousand at September 30, 2026, against $131,787 thousand at December 31, 2025.
  • Goodwill: nil at September 30, 2026, against $26,376 thousand at December 31, 2025.
  • Total liabilities: $81,087 thousand at September 30, 2026, against $123,036 thousand at December 31, 2025.
  • Total stockholders' equity: $219,350 thousand at September 30, 2026, against $295,730 thousand at December 31, 2025.
  • Net cash used in operating activities: $(39,428) thousand in the nine months ended September 30, 2026, against $(60,792) thousand in the prior-year period.
  • Net cash provided by investing activities: $46,828 thousand in the nine months ended September 30, 2026, against $41,792 thousand in the prior-year period.
  • Purchases of property and equipment: $(258) thousand in the nine months ended September 30, 2026, against $(2,710) thousand in the prior-year period.
  • Cash, cash equivalents and restricted cash at end of period: $39,216 thousand at September 30, 2026, against $41,634 thousand at September 30, 2025.
  • Company reports $80.7 million of cash, cash equivalents, marketable securities and restricted cash at quarter end.

Analysis

Quanterix reported third-quarter 2026 total revenues of $34,974 thousand, up 6.3% sequentially according to the company, against $40,233 thousand in the third quarter of 2025. The company describes the quarter as higher than expected and as showing sequential improvement across all its businesses. Product revenue was $25,193 thousand against $26,151 thousand in the prior-year quarter, and service and other revenue was $9,359 thousand against $14,036 thousand. Collaboration and license revenue rose to $422 thousand from $46 thousand. The filing does not print a prior-quarter revenue figure by line, so the sequential change is available only at the total revenue level.

Margins moved in different directions depending on basis. GAAP gross margin was 38.6%, down 90 basis points from the prior year, while adjusted gross margin (non-GAAP) was 47.4%, up 150 basis points. The gap reflects the company's exclusion of amortization of acquired intangible assets and purchase accounting impacts, which the reconciliation shows as $2,857 thousand of acquired intangible amortization within gross profit in the quarter. GAAP operating expenses fell to $35,996 thousand from $53,226 thousand, led by selling, general and administrative expenses of $28,453 thousand against $38,043 thousand and impairment and restructuring costs of $171 thousand against $7,174 thousand. Research and development fell to $7,372 thousand from $8,009 thousand. The loss from operations narrowed to $(22,496) thousand from $(37,325) thousand, and the net loss narrowed to $(21,591) thousand, or $(0.46) per share, from $(33,517) thousand, or $(0.73) per share.

Adjusted EBITDA (non-GAAP) was a loss of $(12,173) thousand, against $(11,885) thousand in the prior-year quarter, with the adjusted EBITDA margin at (34.8)% against (29.5)%. The company's own wording describes this as a decline of 2.4%. The nine-month period is more significant for the balance sheet and the one-time items. Nine-month impairment and restructuring costs were $46,940 thousand in the income statement, and the company reports income from contract termination of $21,596 thousand in the reconciliation, which it describes as one-time income related to terminating a diagnostics development agreement assumed in the Akoya acquisition. Nine-month net cash used in operating activities was $(39,428) thousand, against $(60,792) thousand.

On capital and liquidity, cash, cash equivalents, marketable securities and restricted cash totaled $80.7 million at September 30, 2026. Total assets fell to $300,437 thousand from $418,766 thousand at December 31, 2025, and goodwill was nil after the impairment. The company made no repurchases or dividends in the filing. The 2026 outlook narrows total revenue to $142-146 million, keeps adjusted gross margin (non-GAAP) at 48-50%, and expects approximately $70 million of cash and no debt at year end. The filing does not print the prior revenue range, so the company's narrowing cannot be compared numerically with an earlier outlook. The year-end cash expectation sits below the September 30 balance, which the reader should weigh against the nine-month operating cash outflow.

Management, verbatim

We delivered higher than expected topline growth in the third quarter, with revenues up 6.3% sequentially, despite continued market softness.

Everett Cunningham, President & CEO

The actions we initiated last quarter to improve commercial performance, including reorganizing our teams and adding experienced leadership and discipline, should accelerate our execution in the fourth quarter and beyond

Everett Cunningham, President & CEO

Lastly, we have now established a strong foundation for Quanterix in diagnostics, through strategic investments and partnerships, enabling us to focus on achieving key milestones in Alzheimer's disease testing

Everett Cunningham, President & CEO

Not in the filing

stated, not guessed
  • Prior-quarter (Q2 2026) values for each income statement line; only the sequential percentage for total revenues is printed.
  • Year-over-year percentage change for total revenues, product revenue, service and other revenue, and most cost and expense lines.
  • Year-over-year percentage change for the nine-month period lines.
  • Revenue by business, product line or geography beyond the three revenue lines in the statement of operations; the filing gives no segment disclosure.
  • Drivers for individual revenue lines, product revenue and service and other revenue changes.
  • Prior FY2026 outlook ranges for revenue and adjusted gross margin, so the change in guidance cannot be quantified.
  • Operating expense, operating income and tax rate guidance for FY2026.
  • Reconciliation of forward-looking non-GAAP measures; the filing states this information is not provided.
  • Share repurchase or dividend activity; none is reported.
  • Total assets and equity at the prior-year quarter-end; the balance sheet compares only to December 31, 2025.
  • Consensus estimates, analyst expectations and any share price reaction; none are in the document.
  • Cash balance expressed as a sum of cash, marketable securities and restricted cash; the filing prints $80.7 million only.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about QTRX earnings dates

When is Quanterix's next earnings date?
AlphAI has no date for QTRX yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.